A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease

Trial Profile

A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 Followed by a 12 - Week Treatment Period of LCI699 in Patients With Cushing's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Osilodrostat (Primary)
  • Indications Cushing syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LINC-1; LINC-2
  • Sponsors Novartis
  • Most Recent Events

    • 04 Apr 2017 Results from an Extension to the Linc-2 Study (n=16) presented at The 99th Annual Meeting of the Endocrine Society
    • 01 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Jun 2014 Planned number of patients changed to 39 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top